



10/823,107

**Claim Amendments**

The following amendments use the claims as amended by the Examiner in the notice of allowability mailed on March 3, 2006.

1(currently amended). A compound of Formula (I) or (II)



wherein

A is nitrogen and B is carbon;

R<sup>0</sup> is 2-chlorophenyl, 2-fluorophenyl, 2,4-dichlorophenyl, 2-fluoro-4-chlorophenyl, 2-chloro-4-fluorophenyl, or 2,4-difluorophenyl;

R<sup>1</sup> is 4-chlorophenyl, 4-cyanophenyl, or 4-fluorophenyl;

X is -C(R<sup>2a</sup>)(R<sup>2b</sup>), where R<sup>2a</sup> and R<sup>2b</sup> are each independently hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl;

R<sup>3a</sup> and R<sup>3b</sup> are each independently hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl; and

R<sup>4</sup> is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl, heteroaryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C<sub>1</sub>-C<sub>3</sub>)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a ~~3-to-6-~~ 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, a prodrug of said compound or said salt, or a solvate or hydrate of said compound, said salt or said prodrug.

2(original). The compound of Claim 1 wherein R<sup>4</sup> is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, 3- to 8-membered partially or fully saturated carbocyclic ring(s), and ~~3-to-6-~~ 3- to 8-

10/823,107

membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

3(original). The compound of Claim 2 wherein R<sup>4</sup> is (C<sub>1</sub>-C<sub>8</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>8</sub>)alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-1-yl;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

4(original). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (I);

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

5-12(cancelled).

13(previously presented). The compound of Claim 4 wherein R<sup>2a</sup> and R<sup>2b</sup> are hydrogen;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

14-16(cancelled).

17(previously presented). The compound of Claim 1 selected from the group consisting of

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-isopropyl-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2,2,2-trifluoro-ethyl)-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

10/823,107

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2,2-difluoro-ethyl)-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one; and

3-(4-chloro-phenyl)-2-(2-chloro-phenyl)-6-(2-fluoro-ethyl)-2,4,5,6-tetrahydro-pyrazolo[3,4-c]pyridin-7-one;

or a solvate or hydrate of said compound.



18-32(cancelled).

33(original). The compound of Claim 1, 2 or 3 wherein said compound is a compound of Formula (II);

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

34-44(cancelled).

45(currently amended). A compound of Formula (III) or (IV)



wherein

A is nitrogen and B is carbon;

R<sup>0a</sup>, R<sup>0b</sup>, R<sup>1c</sup>, and R<sup>1b</sup> are each independently halo, (C<sub>1</sub>-C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl, or cyano;

n and m are each independently 0, 1 or 2;

10/823,107

X is  $-C(R^{2a})(R^{2b})$ , where  $R^{2a}$  and  $R^{2b}$  are each independently hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl;

$R^{3a}$  and  $R^{3b}$  are each independently hydrogen, (C<sub>1</sub>-C<sub>4</sub>)alkyl, or halo-substituted (C<sub>1</sub>-C<sub>4</sub>)alkyl; and

$R^4$  is a chemical moiety selected from the group consisting of (C<sub>1</sub>-C<sub>8</sub>)alkyl, aryl, heteroaryl, aryl(C<sub>1</sub>-C<sub>4</sub>)alkyl, a 3- to 8-membered partially or fully saturated carbocyclic ring(s), heteroaryl(C<sub>1</sub>-C<sub>3</sub>)alkyl, 5-6 membered lactone, 5- to 6-membered lactam, and a ~~3- to 6-~~ 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents,

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

46(previously presented). The compound of Claim 45, 78, 79 or 80 wherein said compound is a compound of Formula (III);

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

47-50(cancelled).

51(previously presented). The compound of Claim 46 wherein  $R^{2a}$  and  $R^{2b}$  are hydrogen;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

52(previously presented) The compound of Claim 45, 78, 79 or 80 wherein said compound is a compound of Formula (IV);

a pharmaceutically acceptable salt thereof, a solvate or hydrate of said compound or said salt.

53-56(cancelled).

10/823,107


57(previously presented). The compound of Claim 52 wherein  $R^{2a}$  and  $R^{2b}$  are hydrogen;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

58(previously presented). A pharmaceutical composition comprising (1) a compound of Claim 1, or a solvate or hydrate of said compound or said salt; and (2) a pharmaceutically acceptable excipient, diluent, or carrier.

59-76(cancelled).

77(previously presented). A compound having the following structure



78(currently amended). The compound of Claim 45 wherein  $R^4$  is a chemical moiety selected from the group consisting of  $(C_1-C_8)$ alkyl, aryl( $C_1-C_4$ )alkyl, ~~3- to 6-~~ 3- to 8-membered partially or fully saturated carbocyclic ring(s), and 3- to 8-membered partially or fully saturated heterocycle, where said chemical moiety is optionally substituted with one or more substituents;

a pharmaceutically acceptable salt thereof, or a solvate or hydrate of said compound or said salt.

10/823,107

79(previously presented). The compound of Claim 78 wherein R<sup>4</sup> is (C<sub>1</sub>-C<sub>8</sub>)alkyl, halo-substituted (C<sub>1</sub>-C<sub>8</sub>)alkyl, cyclopentyl, cyclohexyl, piperidin-1-yl, pyrrolidin-1-yl, or morpholin-1-yl;

a pharmaceutically acceptable salt thereof; or a solvate or hydrate of said compound or said salt.

80(previously presented). The compound of Claim 79 wherein R<sup>4</sup> is halo-substituted (C<sub>1</sub>-C<sub>8</sub>)alkyl;

a pharmaceutically acceptable salt thereof; or a solvate or hydrate of said compound or said salt.